These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 10534061)

  • 21. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
    Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
    Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
    Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
    Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS
    Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.
    Bains T; Chen AI; Lemieux A; Hayes-Lattin BM; Leis JF; Dibb W; Maziarz RT
    Leuk Lymphoma; 2014 Mar; 55(3):583-7. PubMed ID: 23697844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.
    Salman B; Al-Khabori M; Al-Huneini M; Al-Rawas A; Dennison D; Al-Za'abi M
    Int J Hematol; 2020 Aug; 112(2):210-216. PubMed ID: 32468179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
    Umeda K; Lin YW; Watanabe K; Adachi S; Usami I; Akiyama Y; Kubota M; Nakahata T
    Rinsho Ketsueki; 2001 Sep; 42(9):685-90. PubMed ID: 11680979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
    Diaz MA; Vicent MG; Madero L
    Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults.
    Lee SH; Son MH; Sung KW; Choi YB; Lee NH; Yoo KH; Koo HH; Lim DH; Shin HJ
    J Neurooncol; 2014 Dec; 120(3):507-13. PubMed ID: 25108776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.
    Lee CC; Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Jou ST; Yao M; Li CC; Yeh SP; Chen MH; Gau JP; Li SS; Wang PN; Liu YC; Wang TF; Tan TD; Lee MY; Yu MS; Wang CC; Lin SC; Chen YC; Su YC; Su KY; Lin KH
    Ann Hematol; 2019 Mar; 98(3):745-752. PubMed ID: 30666432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
    Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
    Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
    Brodsky R; Topolsky D; Crilley P; Bulova S; Brodsky I
    Am J Clin Oncol; 1990 Jun; 13(3):221-5. PubMed ID: 2346127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
    Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
    Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
    Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
    Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.
    Terakura S; Onizuka M; Fukumoto M; Kuwatsuka Y; Kohno A; Ozawa Y; Miyamura K; Inagaki Y; Sawa M; Atsuta Y; Suzuki R; Naoe T; Morishita Y; Murata M;
    Int J Hematol; 2020 Jan; 111(1):84-92. PubMed ID: 31555969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.